TAS-102联合贝伐珠单抗治疗难治性转移性结直肠癌(C-TASK FORCE):一项研究者发起的、开放标签、单臂、多中心1/2期研究
该研究者发起的开放标签单臂多中心1/2期研究在日本4家癌症中心纳入25例难治性转移性结直肠癌患者,评估TAS-102联合贝伐珠单抗的活性与安全性。1期确定2期推荐剂量为TAS-102 35 mg/m2每日两次口服(第1-5天和第8-12天,28天周期)联合贝伐珠单抗5 mg/kg每2周静脉输注。21例接受推荐剂量患者中16周无进展生存率为42.9%(80% CI 27.8-59.0),常见≥3级不良事件为中性粒细胞减少(18例[72%])。作者认为该联合方案具有前景且安全性可控,可能成为难治性转移性结直肠癌的潜在治疗选择。
要点
- 1期确定2期推荐剂量:TAS-102 35 mg/m2每日两次口服(第1-5天和第8-12天,28天周期)联合贝伐珠单抗5 mg/kg每2周静脉输注。
- 21例接受推荐剂量患者中16周无进展生存率为42.9%(80% CI 27.8-59.0)。
- 全部25例中常见≥3级不良事件为中性粒细胞减少18例(72%)、白细胞减少11例(44%)、贫血4例(16%)、发热性中性粒细胞减少4例(16%)、血小板减少3例(12%)。
核心结论
- TAS-102联合贝伐珠单抗具有前景的活性且安全性可控,提示该联合方案可能成为难治性转移性结直肠癌患者的潜在治疗选择。
研究设计与样本
- 研究者发起的、开放标签、单臂、多中心1/2期研究,在日本4家癌症中心开展。
- 纳入25例转移性结直肠癌患者:1期6例,2期19例;患者年龄≥20岁,组织学确诊不可切除转移性结直肠腺癌,对氟嘧啶、伊立替康、奥沙利铂、抗VEGF治疗及抗EGFR治疗(KRAS野生型肿瘤)难治或不耐受,且既往未接受瑞戈非尼治疗,ECOG体能状态评分0或1。
- 1期采用剂量递减设计确定2期推荐剂量;2期患者接受推荐剂量。
- 主要终点为集中评估的16周无进展生存,在最先入组并接受推荐剂量治疗且至少有一次影像学评估的21例患者中分析。
- 研究已完成,注册号UMIN000012883。
主要发现
- 2014年2月25日至2014年7月23日入组25例患者:1期6例,2期19例。
- 接受1期剂量水平TAS-102的6例患者未出现剂量限制性毒性,该剂量被确定为2期推荐剂量。
- 接受推荐剂量的21例患者中9例未发生集中评估的进展事件;16周无进展生存率为42.9%(80% CI 27.8-59.0)。
- 全部25例中常见≥3级不良事件:中性粒细胞减少18例(72%)、白细胞减少11例(44%)、贫血4例(16%)、发热性中性粒细胞减少4例(16%)、血小板减少3例(12%)。
- 治疗相关严重不良事件3例(12%);无治疗相关死亡。
关键数值与推荐
- 2期推荐剂量:TAS-102 35 mg/m2每日两次口服,第1-5天和第8-12天给药,28天周期(1期剂量水平1),联合贝伐珠单抗5 mg/kg每2周静脉输注30分钟。
- 16周无进展生存率42.9%(80% CI 27.8-59.0),基于接受推荐剂量且有至少一次影像学评估的21例患者。
- 全部25例中≥3级中性粒细胞减少18例(72%)、白细胞减少11例(44%)、贫血4例(16%)、发热性中性粒细胞减少4例(16%)、血小板减少3例(12%)。
- 治疗相关严重不良事件3例(12%);无治疗相关死亡。
临床怎么用
- 原文结论认为TAS-102联合贝伐珠单抗具有前景的活性且安全性可控,提示该联合方案可能成为难治性转移性结直肠癌患者的潜在治疗选择。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In patients with heavily treated metastatic colorectal cancer, TAS-102-a combination of trifluridine and tipiracil-has shown a significant overall survival benefit compared with placebo. In preclinical models, TAS-102 plus bevacizumab has shown enhanced activity against colorectal cancer xenografts compared with that for either drug alone. In this phase 1/2 study, we assessed the activity and safety of TAS-102 plus bevacizumab. METHODS: We did this investigator-initiated, open-label, single-arm, multicentre, phase 1/2 trial of TAS-102 plus bevacizumab in four cancer centres in Japan. Eligible patients were aged 20 years or older; had histologically confirmed unresectable, metastatic colorectal adenocarcinoma; were refractory or intolerant to fluoropyrimidine, irinotecan, oxaliplatin, anti-VEGF therapy, and anti-EGFR therapy (for tumours with wild-type KRAS); and had no previous treatment with regorafenib. Patients had to have an Eastern Cooperative Oncology Group performance status of 0 or 1. Using a dose de-escalation design in phase 1, the recommended phase 2 dose (RP2D) was determined for TAS-102 (35 mg/m2 given orally twice daily on days 1-5 and 8-12 in a 28-day cycle for level 1) plus bevacizumab (5 mg/kg, administered by intravenous infusion for 30 min every 2 weeks). In phase 2, patients received the RP2D. The primary endpoint was centrally assessed progression-free survival at 16 weeks, analysed in the first 21 patients to be enrolled and treated with the RP2D who had at least one imaging assessment. This study is completed and registered with the University Hospital Medical Information Network, number UMIN000012883. FINDINGS: Between Feb 25, 2014, and July 23, 2014, we enrolled 25 patients with metastatic colorectal cancer: six patients in phase 1 and 19 patients in phase 2. The six patients who received TAS-102 at level 1 experienced no dose-limiting toxicities and this was deemed the RP2D. Nine of 21 patients who received the RP2D did not have a centrally assessed progression event; 16-week progression-free survival was 42·9% (80% CI 27·8-59·0). The most common grade 3 or worse adverse events as assessed in all 25 patients were neutropenia (18 [72%] patients), leucopenia (11 [44%]), anaemia (four [16%]), febrile neutropenia (four [16%]), and thrombocytopenia (three [12%]). Treatment-related serious adverse events were reported in three (12%) patients. No treatment-related deaths occurred. INTERPRETATION: TAS-102 plus bevacizumab has promising activity with manageable safety, suggesting that this combination might become a potential treatment option for patients with metastatic colorectal cancer in a refractory setting. FUNDING: Taiho Pharmaceutical.
引用
- Kuboki Y, Nishina T, Shinozaki E, et al. TAS-102 plus bevacizumab for patients with metastatic colorectal cancer refractory to standard therapies (C-TASK FORCE): an investigator-initiated, open-label, single-arm, multicentre, phase 1/2 study. Lancet Oncol. 2017. PMID: 28760399. doi:10.1016/S1470-2045(17)30425-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。